LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Ligand Pharmaceuticals Inc

Open

SectorHealthcare

105.66 1.64

Overview

Share price change

24h

Current

Min

103.49

Max

106.33

Key metrics

By Trading Economics

Income

-11M

-42M

Sales

2.5M

45M

P/E

Sector Avg

47.016

51.198

EPS

1.33

Profit margin

-93.643

Employees

68

EBITDA

-11M

-41M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+43.18% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-46M

2B

Previous open

104.02

Previous close

105.66

News Sentiment

By Acuity

13%

87%

17 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2025, 20:45 UTC

Earnings

Broadcom 2Q Sales Climb on Booming AI Demand

5 Jun 2025, 23:45 UTC

Market Talk

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 Jun 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 Jun 2025, 23:30 UTC

Market Talk

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 Jun 2025, 21:32 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 20:45 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:24 UTC

Earnings

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Rev $15B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Net $4.97B >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $1.58 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.03 >AVGO

5 Jun 2025, 20:15 UTC

Earnings

Broadcom Sees 3Q Rev $15.8B >AVGO

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 Jun 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 Jun 2025, 19:22 UTC

Market Talk

Oil Futures Resume Upward Moves -- Market Talk

5 Jun 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 Jun 2025, 18:32 UTC

Market Talk

Gold Slips After Trump-Xi Call -- Market Talk

5 Jun 2025, 18:26 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 Jun 2025, 18:06 UTC

Market Talk

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 Jun 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 Jun 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 Jun 2025, 16:18 UTC

Market Talk

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 Jun 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Global Energy Roundup: Market Talk

5 Jun 2025, 16:12 UTC

Market Talk

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 Jun 2025, 16:03 UTC

Market Talk

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 Jun 2025, 15:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Ligand Pharmaceuticals Inc Forecast

Price Target

By TipRanks

43.18% upside

12 Months Forecast

Average 149.17 USD  43.18%

High 160 USD

Low 135 USD

Based on 7 Wall Street analysts offering 12 month price targets forLigand Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

102.5 / 109.24Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

17 / 380 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.